Next Article in Journal
Incidence and Long-Term Outcomes of Biliary Tract Cancers in Olmsted County, Minnesota from 1976 to 2018
Previous Article in Journal
Association between Cognitive Function and Physical Function, Frailty, and Quality of Life in Older Breast Cancer Survivors
Previous Article in Special Issue
Impact of Hypoxia on Radiation-Based Therapies for Liver Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 15
10.3390/cancers16152719
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Circulatory Agrin Serves as a Prognostic Indicator for Hepatocellular Carcinoma

by
Ankita Kapoor
1,†,
Reza Bayat Mokhtari
2,†,
Sahithi Savithri Sonti
1,
Riya Patel
1,
Anthony George
3,
Kristopher Attwood
3,
Renuka Iyer
1,* and
Sayan Chakraborty
2,4,*
1
Department of Hematology-Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
2
Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
3
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
4
Program of Developmental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2024, 16(15), 2719; https://doi.org/10.3390/cancers16152719
Submission received: 20 June 2024 / Revised: 26 July 2024 / Accepted: 30 July 2024 / Published: 31 July 2024
(This article belongs to the Special Issue Liver Cancers Molecular Biomarkers Predicting Outcome)
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

There is an unmet need for the discovery of new biomarkers for detection and prognosis of liver cancers. Here we reveal the clinical potential of agrin as a key circulatory protein that predicts overall outcomes of liver cancer patients regardless of treatment regimens. Together, our study lays the foundation for further evaluation of agrin as a biomarker for improved clinical management of liver cancers.

Abstract

Hepatocellular carcinoma (HCC), the predominant form of liver cancer, is associated with high mortality rates both in the United States and globally. Despite current advances in immunotherapy regimens, there is a scarcity of biomarkers to guide therapy selection. Alpha-fetoprotein (AFP) and glypican-3 have been proposed as biomarkers for HCC, but they do not provide any prognostic benefit for modeling disease progression. Agrin, a secreted proteoglycan, is frequently overexpressed in HCC and plays prominent role(s) in the liver tumor microenvironment (TME) to promote hepatocarcinogenesis. Here we employed a pilot single-center retrospective investigation to assess the prognostic value of agrin in HCC. Our evidence suggests that elevated serum agrin levels are associated with poor prognosis and performance among HCC patients. Multivariate Cox regression models indicate that secreted agrin serves as a better prognostic indicator compared to AFP that is significantly correlated with other secreted biomarkers (e.g., IL6). Cumulatively, this work demonstrates a promising clinical value of agrin in the detection and prognosis of HCC.

1. Introduction

Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer, accounting for over 90% of liver tumors [1]. According to the American Cancer Society, HCC ranks as the fifth most common cause of cancer-related mortality in males and the seventh most common in females in the United States [1,2]. HCC typically develops in individuals with chronic liver diseases, particularly cirrhosis, which introduces additional risks such as liver failure and contributes to the low 5-year survival rates ranging from 18% to 20% [3]. More than half of HCC-related deaths occur in Asia, primarily due to the prevalence of hepatitis B virus (HBV) infection. However, the incidence of HCC is rising in Western countries as well, driven by the increasing prevalence of non-alcoholic fatty liver disease, alcohol-related liver disease, and complications related to hepatitis C virus (HCV), even with the availability of direct-acting antiviral therapies [2,4,5]. Many patients with HCC are diagnosed at advanced stages and generally have limited treatment options, primarily palliative systemic therapies with suboptimal response rates, leading to 5-year survival rates of less than 5% [6,7]. Despite insights into the broad etiology of HCC, a better understanding of the complex molecular drivers of hepatocarcinogenesis is needed to leverage them as biomarkers and potential therapeutic targets [3].
Alpha-fetoprotein (AFP) has long served as the primary biomarker for HCC patients, playing a crucial role in early HCC screening, often in conjunction with imaging modalities like ultrasound or computed tomography [8]. Additionally, AFP is instrumental in postoperative surveillance for HCC recurrence. Its prognostic value in HCC has been well-established, with higher AFP levels often associated with early recurrence after definitive treatment, leading to diminished overall survival [4,9,10]. However, the prognostic utility of AFP remains a subject of debate in the HCC field. While some studies suggest that AFP levels may predict recurrence-free survival (RFS) following treatment, they do not necessarily correlate with overall survival (OS) [10,11]. Conversely, other studies have found that increased AFP levels independently predict poor OS [9]. Given the conflicting evidence surrounding AFP as a prognostic biomarker, there is a pressing need to identify additional biomarkers that can augment prognosis in HCC patients [5].
Agrin, a secreted heparan sulfate proteoglycan, has emerged as a promising candidate in this context. Agrin is frequently overexpressed and secreted in HCC and plays prominent roles in the liver tumor microenvironment (TME) to promote hepatocarcinogenesis and in the tumor mimicking wound healing and repair [12,13,14,15,16,17,18,19,20,21]. Our preclinical work has characterized agrin in regulating focal adhesion integrity, promoting oncogenesis in HCC models [18]. Agrin enhances cellular proliferation, migration, and oncogenic signaling by sustaining focal adhesion integrity and regulating extracellular matrix (ECM)–cancer cell communications [6,15]. Mechanistically, agrin’s extracellular matrix sensor activity provides oncogenic cues to regulate Arp2/3-dependent ruffling, invadopodia formation, and epithelial–mesenchymal transition through sustained focal adhesion integrity that drives liver tumorigenesis [19]. Furthermore, agrin signaling through the Lrp4-muscle-specific tyrosine kinase (MuSK) forms a critical oncogenic axis [7,19]. Importantly, antibodies targeting agrin have been shown to reduce oncogenic signaling and tumor growth in vivo, highlighting its potential as a therapeutic target [8,20,22].
Our previous studies demonstrated that agrin levels are significantly elevated in HCC tumor tissues and the serum of HCC patients, while low levels were observed in normal livers. Agrin expression was notably linked to tumor size and metastasis, suggesting its involvement in tumor growth and migration [12,20,23]. Additionally, agrin-positive HCC patients had a lower recurrence-free survival rate than agrin-negative patients, underscoring agrin’s potential as a prognostic marker [23,24]. These findings emphasize agrin’s significance in HCC progression and recurrence, warranting further investigation into its mechanistic role and therapeutic implications. To establish the clinical relevance of agrin as a prognostic biomarker in HCC, it is crucial to analyze its association with patient outcomes and other clinicopathological factors. Hence, we designed this study to gain clinical insights into the potential utility of serum agrin levels as a prognostic indicator by examining its correlation with survival outcomes, performance status, and other clinical characteristics in HCC patients [23,24]. In this retrospective study, we examined serum samples from patients with hepatobiliary cancers and explored the role of agrin and its relationship with patient outcomes.

2. Methods

2.1. Study Design and Patients

Our study was a retrospective, single-center investigation aimed at evaluating the role of agrin as a prognostic biomarker in hepatobiliary cancers. To mitigate the inherent limitations of a retrospective design, including potential biases related to patient selection and data collection, we employed a meticulous control matching process and applied rigorous statistical methods. These steps were taken to ensure the reliability of our findings, acknowledging that prospective studies are warranted to further validate our conclusions. The study included 89 patients (62 males, 27 females) newly diagnosed with various hepatobiliary cancers (such as HCC, gallbladder cancer, and intra- and extrahepatic cholangiocarcinoma) between February 2006 and September 2013. The diagnosis of hepatobiliary cancers was confirmed either histologically/cytologically or through hallmark findings evident on radiographic imaging.
A total of 90 controls were selected, matched for age, gender, and BMI, as these factors are known to significantly influence agrin levels. Blood samples collected from patients between February 2006 and September 2013 were subjected to blood tests. The serum concentration of agrin was measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit. Additionally, we aimed to assess the correlation between agrin levels and AFP, a well-established prognostic biomarker in hepatobiliary cancers. Although this study was conducted at a single center, the rigorous methodology and detailed data collection enhance the reliability of our findings. Future multicenter collaborations are planned to further validate these results across diverse populations.

2.2. Statistical Analysis

Patient demographic and clinical characteristics were summarized in the overall sample and by cohort (case versus control) using the mean, median, and standard deviation (SD) for continuous variables and frequencies and relative frequencies for categorical variables. Comparisons were made using GEE linear and multinomial regression models, as appropriate, accounting for within match correlation structure. All model assumptions were verified graphically, and age transformations were applied to the continuous outcomes. The distribution of agrin levels was displayed by cohort using dot plots, and the log-agrin levels compared using a GEE linear regression model.
In the subset of HCC patients, the agrin levels were summarized by levels of clinical and environmental factors using the mean, median, SD, and interquartile range (IQR). Associations were assessed using the Mann–Whitney U and Kruskal–Wallis exact tests, as appropriate. Overall survival was summarized by agrin quartiles using standard Kaplan–Meier methods where the median and 1-year rates were estimated with 95% confidence intervals, and comparisons were made using the log-rank test. A multivariable Cox regression model was used to evaluate the association between agrin levels and overall survival while adjusting for AFP (identified by stepwise selection). Hazard ratios and corresponding 95% confidence intervals were obtained from model estimates.
The correlations between agrin, AFP, and IL6 expression were evaluated using the Spearman correlation coefficient. The ability of these markers to differentiate between HCC (cases) and non-HCC (controls) was evaluated using conditional ROC curves (accounting for the within match correlation structure), from which the corresponding area under the curve (AUC) was obtained for each marker. Additionally, the Youden’s index criterion was used to identify “optimal” decision rules for each marker from which measures of marker performance (i.e., sensitivity, specificity, and positive/negative likelihood ratios) were obtained. As exploratory analyses, multivariable logistic regression models were considered to account for potential confounding factors (smoking, alcohol, and race (white versus non-white)).
All analyses are conducted in SAS v9.4 (Cary, NC, USA) at a significance level of 0.05.

3. Results

3.1. Baseline Characteristics

There was a total of 179 subjects in this study: 89 with newly diagnosed, unresectable hepatobiliary cancers and 90 healthy controls with no history of hepatobiliary cancers. The clinical characteristics of these subjects are listed in Table 1. Both cases and controls had the same proportion of males (68.7%) and females (31.3%), with appropriately matched age groups. A majority of the subjects in both cohorts were white (96.7% of those with cancers of interest and 85.4% of the control group). Within the newly diagnosed cancers there are 49 (55.1%) HCC cases: 8 (16%) stage I, 6 (12%) stage II, 16 (33%) stage III, 15 (31%) stage IV, and 4 (8%) not reported. The analysis of baseline characteristics revealed significant differences in agrin levels among various subgroups of patients. These differences highlight the potential influence of factors such as smoking status, alcohol consumption, and cirrhosis on agrin expression, underscoring the importance of considering these variables when evaluating agrin’s prognostic value [12,23,24].

3.2. Elevated Agrin Levels in Hepatobiliary Cancer Patients

We evaluated the concentration of agrin levels in patients diagnosed with hepatobiliary cancer relative to matched controls from our biorepository, who exhibited no signs of cancer. As delineated in Table 1, individuals with hepatobiliary cancer demonstrated significantly higher agrin concentrations, averaging 7.97 ng/mL compared to 4.27 ng/mL observed in controls without a cancer history (Figure 1, p < 0.001).

3.3. Association of Clinical and Environmental Factors with Agrin Levels

To gain a more comprehensive understanding of the factors influencing agrin production, we investigated the association between serum agrin levels and the following variables: smoking status, alcohol consumption, viral hepatitis, cirrhosis, performance status, AFP levels, and other characteristics of malignancy, such as multifocality, venous thromboembolism, and portal vein involvement. These are listed in Table 2, and the most noteworthy associations are discussed below.
(1)
Performance status (ECOG)
A significant correlation was found between performance status (PS), as assessed by the Eastern Cooperative Oncology Group (ECOG) scale, and elevated agrin levels. Notably, patients with a PS greater than 2 demonstrated higher agrin concentrations, with a mean level of 10.5 ng/mL (p = 0.007). The strong correlation between elevated agrin levels and poorer performance status, as assessed by the ECOG scale, suggests that agrin may serve as a valuable indicator of disease progression and functional impairment in HCC patients [23,24,25]. This finding supports the potential clinical utility of agrin as a prognostic biomarker.
(2)
Smoking
A notable difference in agrin levels was observed based on smoking history when comparing our total patient cohort. While agrin levels in healthy individuals remained stable regardless of smoking history, there was a significant increase in mean agrin levels among smokers compared to non-smokers within the HCC patient population. Specifically, smokers exhibited a mean agrin concentration of 9.49 ng/mL, whereas non-smokers had significantly lower mean agrin concentration of 6.8 ng/mL (see Table 2).

3.4. Survival Outcomes Predicted by Agrin

Lower concentrations of agrin exhibited a significant increased survival rate. Upon stratifying the range of agrin levels, patients with an agrin concentration between 4.9 and 6.3 ng/mL demonstrated a 63% one-year survival rate and a median survival duration of 16 months. In contrast, those with an agrin concentration exceeding 9.3 ng/ml had a markedly lower one-year survival of 14% and a significantly shorter median survival time of 3 months (p = 0.002), as delineated in Figure 2 and Table 3.

3.5. Survival Outcomes Comparing AFP and IL6 with Agrin

Multivariate Cox regression models demonstrated that an agrin concentration exceeding 9.3 ng/mL exhibited robust predictive capacity for survival outcomes (hazard ratio [9] 8.51, p < 0.001) when compared to elevated AFP levels (HR 1.55, p 0.25) as illustrated in Table 4. Furthermore, the presence of elevated AFP levels (>8 ng/mL) exhibited a strong positive association with increased agrin concentrations. Spearman’s rank correlation analysis revealed a significant positive correlation between high AFP levels and elevated agrin concentrations (correlation coefficient: 0.31944; p < 0.001), as depicted in Table 5. Likewise, compared to AFP, there was significant positive correlation between high IL6 and agrin levels (correlation coefficient: 0.43448; p < 0.001) (Table 5).
ROC analysis also revealed that agrin fared well as indicator of HCC but slightly below the level contributed by IL6 (ROC agrin = 0.92 vs. ROC IL6 = 0.97) (Figure 3). For agrin the optimal decision threshold was 4865.52 pg/mL (values above are classified as cases), which produces a sensitivity of 88.8%, specificity of 83.1%, and positive/negative likelihood ratios of 5.25 and 0.13, respectively. For IL6 the optimal decision threshold was 3.086 pg/mL (values above are classified as cases), which produces a sensitivity of 95.5%, specificity of 89.9%, and positive/negative likelihood ratios of 9.45 and 0.05, respectively. When combining the agrin and IL6, the model AUC is 0.96 and achieves a sensitivity of 91.0%, specificity of 91.1%, and positive/negative likelihood ratios of 10.2 and 0.10, respectively. In the multivariate analysis, adjusting for smoking status, alcohol use, and race (white versus non-white); both agrin and IL6 remain as significant predictors of HCC (p = 0.006 and p = 0.011, respectively). As such, higher levels of agrin and IL6 served as poor prognostic indicators for HCC with an HR of 2.57 (Table 5. Model 2 predictors). Considering the overlap of cases versus controls in secreted agrin levels below 10,000 pg/mL, the impact of agrin could be deduced as slightly lower than that of IL6 and biologically could be attributed to distinct cellular pathways initiated by these two secreted factors, suggestive of agrin as a complementing biomarker with IL6.
As shown previously, our analysis revealed that serum agrin was significantly elevated in HCC patients who had a history of smoking or were current smokers (Table 6). Surprisingly, we found that agrin levels were lower in cirrhotic HCC patients and those who were exposed to alcohol intake when compared to controls and the entire patient cohort (Table 6).

4. Discussion

Our study aimed to evaluate agrin levels in patients with newly diagnosed, unresectable hepatobiliary cancers compared to healthy controls without a history of such cancers and to assess the associations between agrin levels and various factors, including smoking, alcohol consumption, viral hepatitis, cirrhosis, performance status, AFP levels, and other malignancy characteristics. The findings revealed that patients with hepatobiliary cancer exhibited significantly elevated agrin levels compared to healthy controls. Moreover, certain factors, such as performance status, smoking history, and elevated AFP levels, were strongly associated with higher agrin levels among cancer patients. As such, our data indicate that agrin may also complement well-known prognostic biomarkers such as IL6 for prediction of HCC.
From our study, elevated levels of agrin might be predictive of cirrhosis but may distinguish cirrhosis-induced HCC. Alcohol is one of the leading causes of liver diseases globally, resulting in a wide range of liver injuries including steatosis, alcoholic hepatitis, cirrhosis, and HCC. In our study, non-alcohol drinkers with HCC had higher agrin levels, probably indicating that other factors like genetics, viral exposure, and non-alcoholic steatohepatitis might be contributing to cirrhosis and thus HCC and might not be due to only alcohol exposure. Agrin levels alone might not distinguish alcohol to cirrhotic conditions, which could be due to a corrupt microenvironment and an interplay between different secreted extracellular matrix factors.
While our study provides significant evidence of agrin’s prognostic value, we acknowledge the need for further mechanistic studies to elucidate the role of agrin in HCC progression. Future research will focus on exploring the molecular pathways through which agrin exerts its effects on tumor growth and metastasis. While our study is indeed a single-center investigation, the comprehensive nature of our data collection and analysis provides a strong foundation for future multicenter studies. We also plan to collaborate with other institutions to validate our findings in a broader patient population.
AFP has been recognized as the principal biomarker for patients with HCC, characterized by a decline in levels following birth and maintenance of low concentrations throughout adulthood [7,26]. It assumes a pivotal role in the early screening of HCC, frequently utilized alongside imaging techniques such as ultrasound or computed tomography [8,27,28]. Furthermore, AFP is essential in the postoperative monitoring for recurrence of HCC. The prognostic significance of AFP in HCC is well-documented, where elevated levels of AFP are often correlated with early recurrence following definitive treatment, consequently leading to reduced overall survival [9,10,29,30,31].
However, the prognostic utility of AFP remains a subject of debate in the literature. While some studies, such as those by Schraiber Ldos et al. and Zhang et al., suggest that AFP levels may predict survival RFS following treatment, they do not necessarily correlate with OS [11,32]. Conversely, Silva et al. attempted to establish the prognostic significance of baseline serum AFP values in HCC patients and found that increased AFP levels independently predict poor OS [9]. Given the conflicting evidence surrounding AFP as a prognostic biomarker, there is a pressing need to identify additional biomarkers that can augment prognosis in HCC patients. These supplementary markers, such as agrin, might not only have the potential to aid in monitoring treatment response but also to guide the implementation of appropriate management strategies.
A significant association was observed between PS, as assessed by the Eastern Cooperative Oncology Group (ECOG) scale, and elevated agrin levels. Notably, patients with a PS greater than 2 exhibited higher agrin concentrations, with a mean value of 10.5 ng/mL. This finding suggests a potential correlation between deteriorating performance status and increased agrin expression, indicating a possible link between disease severity, functional impairment, and agrin secretion. It highlights the potential utility of agrin as a biomarker reflective of disease progression and functional impairment. The association between smoking and elevated agrin levels among patients diagnosed with hepatobiliary cancer is noteworthy. Smokers exhibited higher mean agrin concentrations compared to non-smokers, implying a potential role of smoking in modulating agrin expression within this patient population. This finding underscores the importance of considering lifestyle factors in comprehending cancer biomarkers and their implications for disease progression [33,34,35].
Additionally, elevated levels of AFP exhibited a positive correlation with increased levels of agrin, suggesting a potential interplay between these two biomarkers in hepatobiliary cancer. This correlation between agrin and AFP further underscores the complexity of the tumor microenvironment and its impact on biomarker expression. The positive correlation between elevated agrin and AFP levels, coupled with the superior prognostic capability of agrin in predicting survival outcomes, as demonstrated by the multivariate Cox regression analysis, highlights the potential of agrin as a more reliable prognostic biomarker than AFP in HCC. These findings underscore the need for further exploration of agrin’s role in disease monitoring and treatment stratification. Moreover, survival analysis revealed a significant association between lower levels of agrin and enhanced survival rates among patients with hepatobiliary cancer. Patients with reduced concentrations of agrin demonstrated higher one-year survival rates and extended median survival times compared to those with elevated levels of agrin. Multivariate Cox regression analysis confirmed the concentration of agrin as a robust predictor of survival outcomes, emphasizing its potential clinical utility as a prognostic biomarker in hepatobiliary cancer.
Zhang et al. conducted a study which demonstrated significantly higher agrin expression in HCC samples compared to normal tissue controls (77.1% vs. 25.4%, p < 0.05), indicating a potential role in HCC pathogenesis. Agrin expression exhibited a significant association with tumor size (p = 0.041) and metastasis (p = 0.034), suggesting its involvement in tumor growth and dissemination. Notably, HCC patients with agrin-positive tumors exhibited a lower recurrence-free survival rate compared to those with agrin-negative tumors (p = 0.001), highlighting the potential of agrin as a prognostic marker. These findings underscore the significance of agrin in HCC progression and recurrence, warranting further investigation into its mechanistic role and therapeutic implications [23]. To the best of our knowledge, no previous study has investigated serum agrin expression in HCC patients. Our study fills this gap, offering a novel approach that is more feasible due to the ease of serum measurement. Therefore, our results suggest that agrin has the potential to be used as a prognostic indicator, outperforming AFP.
The findings from this study unveil a crucial role of the proteoglycan agrin in the progression and prognosis of HCC. Agrin, a secreted heparan sulfate proteoglycan, was found to be significantly overexpressed and secreted in HCC tumor tissues and serum samples compared to normal liver tissues. This observation aligns with previous studies that have reported elevated agrin levels in various cancers, including hepatocellular carcinoma, oral squamous cell carcinoma, and cholangiocarcinoma [20,36,37].
Corroborating our findings, Zhang et al. reported that agrin expression was associated with tumor size, metastasis, and lower recurrence-free survival rates in HCC patients, further emphasizing agrin’s significance in HCC progression and recurrence [23]. Additionally, previous studies demonstrated that agrin silencing interfered with cancer cell motility, proliferation, invasion, colony formation, and tumor spheroid formation in oral squamous cell carcinoma, highlighting agrin’s pathological role in cancer progression [37,38,39]. Hence, our study will serve as a platform to analyze the role of secreted agrin as a biomarker in other solid cancers where agrin is mechanistically involved in oncogenic signaling.
While we acknowledge the retrospective nature of our study may introduce certain biases, we have endeavored to minimize these through careful control matching and the application of rigorous statistical analyses. We recognize the value of prospective studies in confirming our findings and recommend them as an essential next step for future research in this area, particularly testing in patients of diverse HCC origins. While our study is limited to a single center, the comprehensive nature of our data collection and analysis provides a strong foundation for future multicenter studies. We plan to collaborate with other institutions to validate our findings in a broader patient population, thereby enhancing the application of our results.
From a therapeutic perspective, our previous work has demonstrated that antibodies targeting agrin reduced oncogenic signaling and tumor growth in vivo, highlighting agrin’s potential as a therapeutic target for antibody therapy in HCC. Furthermore, the increased plasma agrin levels observed in HCC patients may also be exploited to develop diagnostic strategies for early detection and monitoring of the disease.
In conclusion, our study provides compelling evidence for the oncogenic role of agrin in HCC progression and its potential as a prognostic biomarker in addition to being an attractive therapeutic target. The findings contribute to a deeper understanding of the molecular drivers of hepatocarcinogenesis and pave the way for further investigation into the mechanistic roles of agrin and its potential clinical applications in HCC management.

Author Contributions

Study design and conceptualization, R.I. and S.C.; Data acquisition and statistical analysis, S.S.S., A.K., R.B.M., R.P., A.G. and K.A.; Manuscript draft and data analysis, A.K., R.B.M., R.I. and S.C.; Supervision, S.C. All authors have read and agreed to the published version of the manuscript.

Funding

The study was conducted in part by the Start-Up Funds and Developmental Therapeutics (DT) award to S.C. from the Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Roswell Park Comprehensive Cancer Center (protocol code BDR 166123 approved in January 2023).

Informed Consent Statement

All patients are currently deceased. Written informed consents were taken and approved at the time of sample collection by the Data Bank and BioRepository Shared Resource (DBBR), Roswell Park Comprehensive Cancer Center.

Data Availability Statement

All data are available in the manuscript.

Acknowledgments

We thank Orla Maguire from the Flow & Immune Analysis Shared Resource at Roswell Park for ELISA analysis.

Conflicts of Interest

The authors declare no conflict of interests.

Abbreviations

AFP: Alpha-Fetoprotein; ALD: Alcoholic Liver Disease; ECOG: Cooperative Oncology Group; ELISA: Enzyme-Linked Immunosorbent Assay; ECM: Extracellular Matrix; HCC: Hepatocellular Carcinoma; HCV: Hepatitis C Virus; MuSK: Muscle-Specific Tyrosine Kinase; NAFLD: Non-Alcoholic Fatty Liver Disease; OS: Overall Survival; PS: Performance Status; RFS: Recurrence-Free Survival; TME: Tumor Microenvironment.

References

  1. Ioannou, G.N.; Splan, M.F.; Weiss, N.S.; McDonald, G.B.; Beretta, L.; Lee, S.P. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 2007, 5, 938–945.e4. [Google Scholar] [CrossRef] [PubMed]
  2. Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 2023, 73, 17–48. [Google Scholar] [CrossRef] [PubMed]
  3. Golabi, P.; Fazel, S.; Otgonsuren, M.; Sayiner, M.; Locklear, C.T.; Younossi, Z.M. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine 2017, 96, e5904. [Google Scholar] [CrossRef] [PubMed]
  4. Yang, J.D.; Hainaut, P.; Gores, G.J.; Amadou, A.; Plymoth, A.; Roberts, L.R. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 589–604. [Google Scholar] [CrossRef] [PubMed]
  5. Tapper, E.P.; Parikh, N.D. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: Observational study. BMJ 2018, 362, k2817. [Google Scholar] [CrossRef]
  6. Heimbach, J.K.; Kulik, L.M.; Finn, R.S.; Sirlin, C.B.; Abecassis, M.M.; Roberts, L.R.; Zhu, A.X.; Murad, M.H.; Marrero, J.A. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018, 67, 358–380. [Google Scholar] [CrossRef] [PubMed]
  7. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236. [Google Scholar] [CrossRef] [PubMed]
  8. Spangenberg, H.C.; Thimme, R.; Blum, H.E. Serum markers of hepatocellular carcinoma. Semin. Liver Dis. 2006, 26, 385–390. [Google Scholar] [CrossRef] [PubMed]
  9. Silva, J.P.; Gorman, R.A.; Berger, N.G.; Tsai, S.; Christians, K.K.; Clarke, C.N.; Mogal, H.; Gamblin, T.C. The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients. J. Surg. Oncol. 2017, 116, 831–840. [Google Scholar] [CrossRef]
  10. Zhao, Y.J.; Ju, Q.; Li, G.C. Tumor markers for hepatocellular carcinoma. Mol. Clin. Oncol. 2013, 1, 593–598. [Google Scholar] [CrossRef]
  11. Schraiber, L.d.S.; de Mattos, A.A.; Zanotelli, M.L.; Cantisani, G.P.C.; Brandão, A.B.d.M.; Marroni, C.A.; Kiss, G.; Ernani, L.; Marcon, P.d.S. Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma. Medicine 2016, 95, e2478. [Google Scholar] [CrossRef] [PubMed]
  12. Roy, A.M.; Iyer, R.; Chakraborty, S. The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability. Cell Rep. Med. 2023, 4, 101170. [Google Scholar] [CrossRef]
  13. Mokhtari, R.B.; Ashayeri, N.; Baghaie, L.; Sambi, M.; Satari, K.; Baluch, N.; Bosykh, D.A.; Szewczuk, M.R.; Chakraborty, S. The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment. Cancers 2023, 15, 3468. [Google Scholar] [CrossRef]
  14. Chakraborty, S.; Sampath, D.; Lin, M.O.Y.; Bilton, M.; Huang, C.-K.; Nai, M.H.; Njah, K.; Goy, P.-A.; Wang, C.-C.; Guccione, E.; et al. Agrin-Matrix Metalloproteinase-12 axis confers a mechanically competent microenvironment in skin wound healing. Nat. Commun. 2021, 12, 6349. [Google Scholar] [CrossRef] [PubMed]
  15. Chakraborty, S.; Njah, K.; Hong, W. Agrin Mediates Angiogenesis in the Tumor Microenvironment. Trends Cancer 2020, 6, 81–85. [Google Scholar] [CrossRef]
  16. Chakraborty, S.; Hong, W. Oncogenetic engagement with mechanosensing. Nat. Mater. 2020, 19, 707–709. [Google Scholar] [CrossRef] [PubMed]
  17. Njah, K.; Chakraborty, S.; Qiu, B.; Arumugam, S.; Raju, A.; Pobbati, A.V.; Lakshmanan, M.; Tergaonkar, V.; Thibault, G.; Wang, X.; et al. A Role of Agrin in Maintaining the Stability of Vascular Endothelial Growth Factor Receptor-2 during Tumor Angiogenesis. Cell Rep. 2019, 28, 949–965.e7. [Google Scholar] [CrossRef]
  18. Chakraborty, S.; Hong, W. Linking extracellular matrix agrin to the hippo pathway in liver cancer and beyond. Cancers 2018, 10, 45. [Google Scholar] [CrossRef]
  19. Chakraborty, S.; Njah, K.; Pobbati, A.V.; Lim, Y.B.; Raju, A.; Lakshmanan, M.; Tergaonkar, V.; Lim, C.T.; Hong, W. Agrin as a Mechanotransduction Signal Regulating YAP through the Hippo Pathway. Cell Rep. 2017, 18, 2464–2479. [Google Scholar] [CrossRef]
  20. Chakraborty, S.; Lakshmanan, M.; Swa, H.L.; Chen, J.; Zhang, X.; Ong, Y.S.; Loo, L.S.; Akıncılar, S.C.; Gunaratne, J.; Tergaonkar, V.; et al. An oncogenic role of Agrin in regulating focal adhesion integrity in hepatocellular carcinoma. Nat. Commun. 2015, 6, 6184. [Google Scholar] [CrossRef]
  21. Lin, M.O.Y.; Sampath, D.; Bosykh, D.A.; Wang, C.; Wang, X.; Subramaniam, T.; Han, W.; Hong, W.; Chakraborty, S. YAP/TAZ Drive Agrin-Matrix Metalloproteinase-12 Mediated Diabetic Skin Wound Healing. J. Investig. Dermatol. 2024. [Google Scholar] [CrossRef]
  22. Chen, J.; Chen, H.; Dong, X.; Hui, T.; Yan, M.; Ren, D.; Zou, S.; Wang, S.; Fei, E.; Zhang, W.; et al. Deficiency of skeletal muscle Agrin contributes to the pathogenesis of age-related sarcopenia in mice. Cell Death Dis. 2024, 15, 201. [Google Scholar] [CrossRef] [PubMed]
  23. Zhang, Q.J.; Wan, L.; Xu, H.F. High expression of agrin is associated with tumor progression and poor prognosis in hepatocellular carcinoma. Math. Biosci. Eng. 2019, 16, 7375–7383. [Google Scholar] [CrossRef] [PubMed]
  24. Kapoor, A.; Sonti, S.; Patel, R.J.; George, A.; Attwood, K.; Thanikachalam, K.; Iyer, R.V.; Chakraborty, S. Agrin as a prognostic biomarker in hepatocellular carcinoma. J. Clin. Oncol. 2024, 42, 552. [Google Scholar] [CrossRef]
  25. Gupta, A.; Zorzi, J.; Ho, W.J.; Baretti, M.; Azad, N.S.; Griffith, P.; Dao, D.; Kim, A.; Philosophe, B.; Georgiades, C.; et al. Relationship of Hepatocellular Carcinoma Stage and Hepatic Function to Health-Related Quality of Life: A Single Center Analysis. Healthcare 2023, 11, 2571. [Google Scholar] [CrossRef] [PubMed]
  26. Yeo, Y.H.; Lee, Y.-T.; Tseng, H.-R.; Zhu, Y.; You, S.; Agopian, V.G.; Yang, J.D. Alpha-fetoprotein: Past, present, and future. Hepatol. Commun. 2024, 8, e0422. [Google Scholar] [CrossRef] [PubMed]
  27. Huang, D.; Zhang, J.; Xu, J.; Niu, Q.; Zhou, D. Utility of Alpha-Fetoprotein and Ultrasound in the Diagnosis and Prognosis of Patients with Hepatocellular Liver Cancer. J. Multidiscip. Healthc. 2024, 17, 1819–1826. [Google Scholar] [CrossRef] [PubMed]
  28. Wang, W.; Wei, C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020, 7, 308–319. [Google Scholar] [CrossRef] [PubMed]
  29. Xu, J.; An, S.; Lu, Y.; Li, L.; Wu, Z.Q.; Xu, H.G. Preoperative alpha fetoprotein, total bilirubin, fibrinogen, albumin, and lymphocytes predict postoperative survival in hepatocellular carcinoma. Cancer Med. 2023, 12, 13319–13328. [Google Scholar] [CrossRef]
  30. Liu, C.; Li, Z.; Zhang, Z.; Li, J.; Xu, C.; Jia, Y.; Zhang, C.; Yang, W.; Wang, W.; Wang, X.; et al. Prediction of survival and analysis of prognostic factors for patients with AFP negative hepatocellular carcinoma: A population-based study. BMC Gastroenterol. 2024, 24, 93. [Google Scholar] [CrossRef]
  31. Lin, K.-Y.; Chen, Q.-J.; Tang, S.-C.; Lin, Z.-W.; Zhang, J.-X.; Zheng, S.-M.; Li, Y.-T.; Wang, X.-M.; Lu, Q.; Fu, J.; et al. Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): A large cohort study of 2770 patients. BMC Cancer 2023, 23, 1190. [Google Scholar] [CrossRef] [PubMed]
  32. Zhang, L.; Ge, N.-L.; Chen, Y.; Xie, X.-Y.; Yin, X.; Gan, Y.-H.; Zhang, B.-H.; Zhang, J.-B.; Chen, R.-X.; Wang, Y.-H.; et al. Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patients. Med. Oncol. 2015, 32, 77. [Google Scholar] [CrossRef] [PubMed]
  33. Sharman, R.; Harris, Z.; Ernst, B.; Mussallem, D.; Larsen, A.; Gowin, K. Lifestyle Factors and Cancer: A Narrative Review. Mayo Clin. Proc. Innov. Qual. Outcomes 2024, 8, 166–183. [Google Scholar] [CrossRef] [PubMed]
  34. Kjerulff, B.; Dowsett, J.; Jacobsen, R.L.; Gladov, J.; Larsen, M.H.; Lundgaard, A.T.; Banasik, K.; Westergaard, D.; Mikkelsen, S.; Dinh, K.M.; et al. Lifestyle and demographic associations with 47 inflammatory and vascular stress biomarkers in 9876 blood donors. Commun. Med. 2024, 4, 50. [Google Scholar] [CrossRef] [PubMed]
  35. Bian, Z.; Zhang, R.; Yuan, S.; Fan, R.; Wang, L.; Larsson, S.C.; Theodoratou, E.; Zhu, Y.; Wu, S.; Ding, Y.; et al. Healthy lifestyle and cancer survival: A multinational cohort study. Int. J. Cancer 2024, 154, 1709–1718. [Google Scholar] [CrossRef] [PubMed]
  36. He, M.; Cheng, C.; Tu, J.; Ji, S.; Lou, D.; Bai, B. Agrin expression is correlated with tumor development and poor prognosis in cholangiocarcinoma. J. Int. Med. Res. 2021, 49, 03000605211009722. [Google Scholar] [CrossRef] [PubMed]
  37. Kawahara, R.; Granato, D.C.; Carnielli, C.M.; Cervigne, N.K.; Oliveria, C.E.; Martinez, C.A.R.; Yokoo, S.; Fonseca, F.P.; Lopes, M.; Santos-Silva, A.R.; et al. Agrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma. PLoS ONE 2014, 9, e115004. [Google Scholar] [CrossRef] [PubMed]
  38. Rivera, C.; Zandonadi, F.S.; Sánchez-Romero, C.; Soares, C.D.; Granato, D.C.; González-Arriagada, W.A.; Paes Leme, A.F. Agrin has a pathological role in the progression of oral cancer. Br. J. Cancer 2018, 118, 1628–1638. [Google Scholar] [CrossRef]
  39. Adamiok-Ostrowska, A.; Grzanka, M.; Czarnocka, B. Agrin is a novel oncogenic protein in thyroid cancer. Oncol. Lett. 2023, 26, 483. [Google Scholar] [CrossRef]
Cancers 16 02719 g001
Figure 1. Dot Plot Showing Agrin Concentration in Cases versus Controls.
Figure 1. Dot Plot Showing Agrin Concentration in Cases versus Controls.
Cancers 16 02719 g001
Cancers 16 02719 g002
Figure 2. Survival Summary by Agrin Quartiles (Subset: HCC Patients Only).
Figure 2. Survival Summary by Agrin Quartiles (Subset: HCC Patients Only).
Cancers 16 02719 g002
Cancers 16 02719 g003
Figure 3. ROC curves of Agrin and IL6 as prognostic indicators for HCC.
Figure 3. ROC curves of Agrin and IL6 as prognostic indicators for HCC.
Cancers 16 02719 g003
Table 1. Summary of Patient Demographic Characteristics in Cases versus Controls.
Table 1. Summary of Patient Demographic Characteristics in Cases versus Controls.
ControlCaseOverallp-Value
N90 (50.3)89 (49.7)179 (100%)
AgeMean/Std/N60.34/12.77/9060.37/12.50/8960.36/12.60/1790.161
Median/Min/Max59.00/23.00/85.0059.00/24.00/86.0059.00/23.00/86.00
GenderMale61 (67.8%)62 (69.7%)123 (68.7%)0.162
Female29 (32.2%)27 (30.3%)56 (31.3%)
BMIMean/Std/N28.70/5.51/9028.91/6.04/8928.81/5.76/1790.797
Median/Min/Max27.43/18.24/48.8228.35/17.35/49.7227.70/17.35/49.72
RaceWhite87 (96.7%)76 (85.4%)163 (91.1%)0.003
Black3 (3.3%)8 (9.0%)11 (6.1%)
Asian 1 (1.1%)1 (0.6%)
Native American 2 (2.2%)2 (1.1%)
Multiracial 1 (1.1%)1 (0.6%)
Other 1 (1.1%)1 (0.6%)
SmokingNever53 (59.6%)27 (30.3%)80 (44.9%)0.007
Current5 (5.6%)29 (32.6%)34 (19.1%)
Former31 (34.8%)33 (37.1%)64 (36.0%)
AlcoholNo14 (15.6%)24 (27.0%)38 (21.2%)0.024
Current76 (84.4%)35 (39.3%)111 (62.0%)
Former 30 (33.7%)30 (16.8%)
CirrhosisNo86 (100.0%)62 (69.7%)148 (84.6%)<0.001
Yes 27 (30.3%)27 (15.4%)
HBVNo 84 (94.4%)84 (94.4%)
Yes 5 (5.6%)5 (5.6%)
HCVNo 62 (69.7%)62 (69.7%)
Yes 27 (30.3%)27 (30.3%)
CholangitisNo 89 (100.0%)89 (100.0%)
Type of CancerLiver and Bile Ducts 79 (88.8%)79 (88.8%)
Gallbladder 8 (9.0%)8 (9.0%)
Other Biliary Tract 2 (2.2%)2 (2.2%)
AJCC StageI 11 (13.3%)11 (13.3%)
II 9 (10.8%)9 (10.8%)
III 24 (28.9%)24 (28.9%)
IV 39 (47.0%)39 (47.0%)
ECOG0 28 (31.5%)28 (31.5%)
1 41 (46.1%)41 (46.1%)
2+ 20 (22.5%)20 (22.5%)
Uncontrolled Pain at PresentationNo 34 (38.2%)34 (38.2%)
Yes 55 (61.8%)55 (61.8%)
AFPMean/Std/N././015,065.88/44,978.87/5915,065.88/44,978.87/59
Median/Min/Max././.181.70/1.30/307,716.6181.70/1.30/307,716.6
Multifocal Cancer on CTNo 32 (36.0%)32 (36.0%)
Yes 57 (64.0%)57 (64.0%)
Portal Vein Thrombosis on CTNo 59 (66.3%)59 (66.3%)
Yes 30 (33.7%)30 (33.7%)
VTE at Time of DiagnosisNo 79 (88.8%)79 (88.8%)
Yes 10 (11.2%)10 (11.2%)
Agrin LevelMean/Std/N4.27/1.03/907.97/5.81/896.11/4.54/179<0.001
Median/Min/Max4.12/1.87/7.906.34/3.10/4.514.90/1.87/45.10
Table 2. Summary of Agrin Levels by Patient Demographic Characteristics (Subset: HCC Patients Only).
Table 2. Summary of Agrin Levels by Patient Demographic Characteristics (Subset: HCC Patients Only).
nMean (SD)Median (IQR)p-Value
SmokingNever276861.3 (3961.3)5835.4 (4878.4–8189.7)0.32
Current299490.7 (8433.5)6669.2 (5288.4–10,006.4)
Former337541.8 (3841.1)6545.2 (4871.2–9406.4)
AlcoholNo249676.0 (8774.8)6849.8 (5702.9–9860.4)0.39
Current357602.6 (4738.4)5890.3 (4878.4–9391.2)
Former307035.1 (3438.1)6278.9 (4724.4–8189.7)
CirrhosisNo628224.4 (6808.3)6055.9 (4871.2–9391.2)0.25
Yes277387.2 (2297.2)6867.2 (5557.2–9319.2)
HBVNo848083.5 (5953.3)6344.2 (4999.0–9398.8)0.49
Yes56071.0 (2072.1)5835.4 (4878.4–7587.8)
HCVNo628086.6 (6462.3)6112.5 (4878.4–9391.2)0.55
Yes277703.6 (4056.0)6545.2 (5197.0–8616.4)
CholangitisNo897970.4 (5817.2)6343.2 (4961.1–9319.2)
ECOG0286137.0 (2336.1)6010.2 (4021.7–7793.8)0.007
1417984.0 (7004.6)6082.7 (5197.0–7989.7)
2+2010,509.2 (5826.1)10,384.2 (6419.4–12,198.2)
Uncontrolled Pain at PresentationNo347674.2 (7443.8)5959.0 (4547.8–7836.4)0.09
Yes558153.5 (4603.8)6646.5 (5197.0–10,006.4)
AFPNormal (≤8)135546.9 (1457.2)5890.3 (4724.4–6212.6)0.03
Elevated (>8)468705.8 (6900.8)6590.4 (5231.6–9406.4)
Multifocal Cancer on CTNo328347.9 (7470.8)6254.5 (5152.1–9355.2)0.96
Yes577758.5 (4706.7)6345.2 (4949.2–8616.4)
Portal Vein Thrombosis on CTNo598323.6 (6887.2)6202.4 (4865.5–9319.2)0.50
Yes307275.8 (2658.2)6647.4 (5288.4–9406.4)
VTE at Time of DiagnosisNo797819.3 (5954.1)6212.6 (4878.4–8614.4)0.13
Yes109164.3 (4674.9)8388.8 (5673.1–10,286.4)
Table 3. Survival outcomes based on Agrin Quartiles.
Table 3. Survival outcomes based on Agrin Quartiles.
1-yr Surv. Rate
(95% CI)		Median Surv.
(95% CI)		SampleLog Rank
p-Value
Total0.36 (0.26, 0.46)8.0 (5.0, 11.0)E = 77 C = 9 T = 86p = 0.002
Q1 (≤4961.14)0.45 (0.24, 0.64)11.0 (5.0, 24.0)E = 18 C = 4 T = 22
Q1–Q2 (4961.14–6343.20)0.63 (0.40, 0.80)16.0 (5.0, 21.0)E = 19 C = 3 T = 22
Q2–Q3 (6343.20–9319.20)0.20 (0.06, 0.39)6.0 (5.0, 9.0)E = 18 C = 2 T = 20
Q4 (≥9319.20)0.14 (0.03, 0.31)3.0 (2.0, 10.0)E = 22 C = 0 T = 22
Table 4. Univariate and Multivariate Cox Regression Modeling (Subset: HCC Patients Only).
Table 4. Univariate and Multivariate Cox Regression Modeling (Subset: HCC Patients Only).
Univariate Cox Regression Models
AgrinHazard Ratio (95% CL)p-Value
Q1 (≤4961.14)Ref.0.0064
Q1–Q2 (4961.14–6343.20)1.022 (0.536–1.951)0.9468
Q2–Q3 (6343.20–9319.20)1.530 (0.792–2.953)0.2053
Q4 (≥9319.20)2.659 (1.409–5.019)0.0026
Multivariate Cox Regression Models
Model 1 Predictors: Agrin and AFP (Elevated vs. Normal)
AgrinHazard Ratio (95% CL)p-Value
Q1 (≤4961.14)Ref.<0.0001
Q1–Q2 (4961.14–6343.20)1.094 (0.487–2.456)0.8284
Q2–Q3 (6343.20–9319.20)2.067 (0.871–4.903)0.0997
Q4 (≥9319.20)8.157 (3.085–21.567)<0.0001
AFPHazard Ratio (95% CL)p-Value
Normal (≤8)Ref.0.2534
Elevated (>8)1.553 (0.730–3.306)
Table 5. Spearman Correlation Coefficients and multivariate models between Agrin and AFP/IL6.
Table 5. Spearman Correlation Coefficients and multivariate models between Agrin and AFP/IL6.
Spearman Correlation Coefficients
Prob > |r| under H0: Rho = 0
Number of Observations
AgrinAFPIL6
Agrin1.000000.319440.43448
0.0137<0.0001
895989
AFP0.319441.000000.19852
0.0137 0.1317
595959
Multivariate Cox Regression Models
Model 2 Predictors: Agrin and IL6 (Dichotomized at Median)
AgrinHazard Ratio (95% CL)p-Value
Q1 (≤4961.14)Ref.0.0198
Q1–Q2 (4961.14–6343.20)1.005 (0.514–1.965)0.9881
Q2–Q3 (6343.20–9319.20)1.493 (0.738–3.020)0.2645
Q4 (≥9319.20)2.576 (1.258–5.275)0.0097
IL6Hazard Ratio (95% CL)p-Value
≤Median (17.199)Ref.0.8509
>Median (17.199)1.050 (0.629–1.752)
Table 6. Evaluation of serum agrin levels with smoking, alcohol, and cirrhosis conditions amongst all patients versus controls.
Table 6. Evaluation of serum agrin levels with smoking, alcohol, and cirrhosis conditions amongst all patients versus controls.
Patient CharacteristicCasesControlsp-Value
NAgrin Level
Mean (SD)		NAgrin Level
Mean (SD)
SmokingNever276861.3 (3961.3)534174.9 (969.4)0.0001
Current299490.7 (8433.5)54115.2 (694.1)0.0048
Former337541.8 (3841.1)314518.1 (1154.3)<0.0001
AlcoholNo249676.0 (8774.8)144795.4 (894.4)0.0008
Current357602.6 (4738.4)764182.1 (1032.0)<0.0001
Former307035.1 (3438.1)
CirrhosisNo628224.4 (6808.3)864315.6 (1030.8)<0.0001
Yes277387.2 (2297.2)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kapoor, A.; Bayat Mokhtari, R.; Sonti, S.S.; Patel, R.; George, A.; Attwood, K.; Iyer, R.; Chakraborty, S. Circulatory Agrin Serves as a Prognostic Indicator for Hepatocellular Carcinoma. Cancers 2024, 16, 2719. https://doi.org/10.3390/cancers16152719

AMA Style

Kapoor A, Bayat Mokhtari R, Sonti SS, Patel R, George A, Attwood K, Iyer R, Chakraborty S. Circulatory Agrin Serves as a Prognostic Indicator for Hepatocellular Carcinoma. Cancers. 2024; 16(15):2719. https://doi.org/10.3390/cancers16152719

Chicago/Turabian Style

Kapoor, Ankita, Reza Bayat Mokhtari, Sahithi Savithri Sonti, Riya Patel, Anthony George, Kristopher Attwood, Renuka Iyer, and Sayan Chakraborty. 2024. "Circulatory Agrin Serves as a Prognostic Indicator for Hepatocellular Carcinoma" Cancers 16, no. 15: 2719. https://doi.org/10.3390/cancers16152719

APA Style

Kapoor, A., Bayat Mokhtari, R., Sonti, S. S., Patel, R., George, A., Attwood, K., Iyer, R., & Chakraborty, S. (2024). Circulatory Agrin Serves as a Prognostic Indicator for Hepatocellular Carcinoma. Cancers, 16(15), 2719. https://doi.org/10.3390/cancers16152719

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop